Filtered By:
Condition: Atrial Fibrillation
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 563 results found since Jan 2013.

Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
ConclusionsFor stroke prevention in AF, direct OACs seem to be more effective and safer than usual care, and apixaban (5  mg twice daily) had the best profile. For VTE, there was no strong evidence that direct OACs were better than usual care. Education and pharmacist management could improve coagulation control. Both clinicians and patients rated efficacy and safety as the most important factors in managing AF and V TE.Systematic review registrationPROSPERO CRD42017084263 —one deviation; efficacy and safety were from one review.
Source: Systematic Reviews - October 28, 2022 Category: International Medicine & Public Health Source Type: research

Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry.
CONCLUSIONS: The Fushimi AF Registry provides a unique snapshot of current AF management in an urban community in Japan. PMID: 23403369 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 8, 2013 Category: Cardiology Authors: Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji H, Furuke K, On behalf of the Fushimi AF Registry investigators Tags: J Cardiol Source Type: research

Ultra Hyperacute MR Findings in Reperfusion Hemorrhage (P01.243)
CONCLUSIONS: The clinician should be aware that hypointense signal on GRE typically associated with hyperacute intracerebral hemorrhage may be absent if imaged very early.Disclosure: Dr. Samuels has nothing to disclose. Dr. Jhaveri has nothing to disclose. Dr. Conners has nothing to disclose. Dr. Cutting has received personal compensation for activities with F1000. Dr. Prabhakaran has nothing to disclose. Dr. Lee has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Samuels, J., Jhaveri, M., Conners, J., Cutting, S., Prabhakaran, S., Lee, V. Tags: P01 Cerebrovascular Disease I Source Type: research

Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention
ConclusionsIn real-life AF patients with indication for multiple antithrombotic drugs after MI/PCI, OAC and clopidogrel was equal or better on both benefit and safety outcomes compared to triple therapy.
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - September 3, 2013 Category: Radiology Source Type: research

Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial
Conclusions: In patients with AF, apixaban more often prevented stroke or systemic embolism and death and caused less bleeding than warfarin, regardless of the presence of prior CAD. Given the common occurrence of AF and CAD and the higher rates of cardiovascular events and death, our results indicate that apixaban may be a better treatment option than warfarin for these high-risk patients.
Source: International Journal of Cardiology - November 4, 2013 Category: Cardiology Authors: Maria Cecilia Bahit, Renato D. Lopes, Daniel M. Wojdyla, Stefan H. Hohnloser, John H. Alexander, Basil S. Lewis, Philip E. Aylward, Freek W.A. Verheugt, Matyas Keltai, Rafael Diaz, Michael Hanna, Christopher B. Granger, Lars Wallentin Tags: Original Articles Source Type: research

Integrating Real-Time Clinical Information to Provide Estimates of Net Clinical Benefit of Antithrombotic Therapy for Patients With Atrial Fibrillation Original Articles
Conclusions— Use of a decision support tool that integrates patient-specific stroke and bleeding risk could result in significant gains in quality-adjusted life expectancy for a primary care population of patients with atrial fibrillation.
Source: Circulation: Cardiovascular Quality and Outcomes - September 16, 2014 Category: Cardiology Authors: Eckman, M. H., Wise, R. E., Speer, B., Sullivan, M., Walker, N., Lip, G. Y. H., Kissela, B., Flaherty, M. L., Kleindorfer, D., Khan, F., Kues, J., Baker, P., Ireton, R., Hoskins, D., Harnett, B. M., Aguilar, C., Leonard, A., Prakash, R., Arduser, L., Cost Tags: Health policy and outcome research, Primary prevention, Coumarins, Thrombosis risk factors, Arrhythmias, clinical electrophysiology, drugs, Anticoagulants, Epidemiology Original Articles Source Type: research

Combined anticoagulation and antiplatelet therapy in AF patients: why do we not follow guidelines?
While current European guidelines recommend oral anticoagulation treatment over antiplatelet therapy for the prevention of ischaemic stroke in patients with non-valvular atrial fibrillation (AF) with a 64% stroke risk reduction by warfarin treatment versus placebo and a 39% risk reduction versus aspirin,1 single or dual antiplatelet therapy is the guideline recommended first-line treatment strategy for patients with peripheral and/or coronary artery disease with and without intervention to prevent recurrences and major adverse cardiac events.2–7 Antiplatelet therapy is also recommended in patients with ischaemic stro...
Source: Heart - September 23, 2014 Category: Cardiology Authors: Brandes, A. Tags: Drugs: cardiovascular system, Acute coronary syndromes, Venous thromboembolism Editorials Source Type: research

Individualized antithrombotic therapy.
Conclusion: An extensive therapeutic arsenal to interfere with clot formation requires an individualized approach considering the disease condition and co-morbidities of the patient, the anticoagulants' and patientcharacteristics. This review builds on and extens previous publications of the authors on this topic. PMID: 25597592 [PubMed - as supplied by publisher]
Source: Hamostaseologie - January 19, 2015 Category: Hematology Authors: Lüscher TF, Steffel J Tags: Hamostaseologie Source Type: research

Efficacy and Safety of Oral Anticoagulants Versus Aspirin for Patients With Atrial Fibrillation: A Meta-Analysis
Abstract: The purpose of this study was to perform a meta-analysis comparing the effectiveness and safety of anticoagulation to antiplatelet therapy for the prevention of thromboembolic events in patients with atrial fibrillation (AF). MEDLINE, Cochrane, EMBASE, and Google Scholar databases were searched for studies published through May 31, 2014. Randomized controlled trials comparing anticoagulants (warfarin) and antiplatelet therapy in patients with AF were included. The primary outcomes were the rates of stroke and systemic embolism. Secondary outcomes included the rates of hemorrhage/major bleeding and death. Pooled o...
Source: Medicine - January 1, 2015 Category: Internal Medicine Tags: Article: Systematic Review and Meta-Analysis Source Type: research

Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial
Conclusions: Based on AVERROES trial results, among patients with AF unsuitable for warfarin therapy, apixaban use was estimated to be associated with a mean medical cost avoidance of US$735 in a patient-year relative to aspirin. The primary driver was the significant reduction in ischemic stroke rate. The medical cost reduction associated with apixaban use was consistent in sensitivity analyses.
Source: Clinical and Applied Thrombosis/Hemostasis - February 27, 2015 Category: Hematology Authors: Amin, A., Deitelzweig, S., Jing, Y., Makenbaeva, D., Wiederkehr, D., Lin, J., Graham, J. Tags: Original Articles Source Type: research

Antiplatelet Therapy in Japanese Patients with Atrial Fibrillation without Oral Anticoagulants: Pooled Analysis of Shinken Database, J-RHYTHM Registry and Fushimi AF Registry
Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke. Oral anticoagulants (OAC) are effective for stroke prevention in patients with AF, and recent evidences have revealed the efficacy and safety of non-vitamin K antagonist OAC (NOAC) as well as warfarin. Although aspirin was shown to be inferior to warfarin or apixaban in preventing stroke [1,2], it is still prescribed to many AF patients in clinical practice [3–5]. This may be because physicians perceived it to be a safer and more convenient alternative to OAC.
Source: International Journal of Cardiology - April 22, 2015 Category: Cardiology Authors: Hisashi Ogawa, Masaharu Akao, Shinya Suzuki, Takeshi Yamashita, Ken Okumura, Hirotsugu Atarashi, Hiroshi Inoue Tags: Letter to the Editor Source Type: research

Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis
Conclusion: Providing patients who declined warfarin therapy with information about their genetic risk of AF would be cost effective if this genetic risk information resulted in modest increases in adherence.
Source: BMC Cardiovascular Disorders - September 29, 2015 Category: Cardiology Authors: Dov ShiffmanMarco PerezLance BareJudy LouieAndre ArellanoJames Devlin Source Type: research

Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin　- Insights From the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: HDE had a greater relative efficacy and safety in EA compared with Japan that was only partially explained by differences in baseline characteristics and TTR. PMID: 26460886 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 9, 2015 Category: Cardiology Authors: Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, Mercuri M, Ruff CT, Giugliano RP Tags: Circ J Source Type: research

Targeted Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment with an Insertable Cardiac Monitor: The Rhythm Evaluation for Anticoagulation with Continuous Monitoring (REACT.COM) Pilot Study
Conclusions: A targeted strategy of ICM‐guided intermittent NOAC administration is feasible. A large‐scale trial is necessary to evaluate the safety of this approach.This article is protected by copyright. All rights reserved
Source: Journal of Cardiovascular Electrophysiology - October 29, 2015 Category: Cardiology Authors: ROD PASSMAN, PETER LEONG‐SIT, ADIN‐CRISTIAN ANDREI, ANNA HUSKIN, TODD T. TOMSON, RICHARD BERNSTEIN, ETHAN ELLIS, JONATHAN WAKS, PETER ZIMETBAUM Tags: Original Article Source Type: research